TY - JOUR
T1 - Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia
AU - Taher, Ali T.
AU - Porter, John B.
AU - Viprakasit, Vip
AU - Kattamis, Antonis
AU - Chuncharunee, Suporn
AU - Sutcharitchan, Pranee
AU - Siritanaratkul, Noppadol
AU - Origa, Raffaella
AU - Karakas, Zeynep
AU - Habr, Dany
AU - Zhu, Zewen
AU - Cappellini, Maria Domenica
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Summary: Liver iron concentration (LIC) assessment by magnetic resonance imaging (MRI) remains the gold standard to diagnose iron overload and guide iron chelation therapy in patients with non-transfusion-dependent thalassaemia (NTDT). However, limited access to MRI technology and expertise worldwide makes it practical to also use serum ferritin assessments. The THALASSA (assessment of Exjade® in non-transfusion-dependent THALASSemiA patients) study assessed the efficacy and safety of deferasirox in iron-overloaded NTDT patients and provided a large data set to allow exploration of the relationship between LIC and serum ferritin. Using data from screened patients and those treated with deferasirox for up to 2 years, we identified clinically relevant serum ferritin thresholds (for when MRI is unavailable) for the initiation of chelation therapy (>800 μg/l), as well as thresholds to guide chelator dose interruption (2000 μg/l). (clinicaltrials.gov identifier: NCT00873041).
AB - Summary: Liver iron concentration (LIC) assessment by magnetic resonance imaging (MRI) remains the gold standard to diagnose iron overload and guide iron chelation therapy in patients with non-transfusion-dependent thalassaemia (NTDT). However, limited access to MRI technology and expertise worldwide makes it practical to also use serum ferritin assessments. The THALASSA (assessment of Exjade® in non-transfusion-dependent THALASSemiA patients) study assessed the efficacy and safety of deferasirox in iron-overloaded NTDT patients and provided a large data set to allow exploration of the relationship between LIC and serum ferritin. Using data from screened patients and those treated with deferasirox for up to 2 years, we identified clinically relevant serum ferritin thresholds (for when MRI is unavailable) for the initiation of chelation therapy (>800 μg/l), as well as thresholds to guide chelator dose interruption (2000 μg/l). (clinicaltrials.gov identifier: NCT00873041).
KW - Chelation therapy
KW - Iron overload
KW - Liver iron concentration
KW - Non-transfusion-dependent thalassaemia
KW - Serum ferritin
UR - http://www.scopus.com/inward/record.url?scp=84923800477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923800477&partnerID=8YFLogxK
U2 - 10.1111/bjh.13119
DO - 10.1111/bjh.13119
M3 - Article
C2 - 25212456
AN - SCOPUS:84923800477
VL - 168
SP - 284
EP - 290
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -